PMID- 25766339
OWN - NLM
STAT- MEDLINE
DCOM- 20160726
LR  - 20181113
IS  - 0972-2823 (Electronic)
IS  - 0022-3859 (Print)
IS  - 0022-3859 (Linking)
VI  - 61
IP  - 2
DP  - 2015 Apr-Jun
TI  - Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.
PG  - 88-91
LID - 10.4103/0022-3859.150446 [doi]
AB  - BACKGROUND: Hodgkin's lymphoma displays distinct epidemiological attributes in 
      Asian population thus making it relevant to study whether there are any 
      differences in treatment outcomes too when treated with current standard of care. 
      AIM: To evaluate the treatment outcomes of de-novo advanced stage HL in adults. 
      MATERIALS AND METHODS: This retrospective study included de-novo advanced stage 
      HL patients (>/=15 years) registered at our center from January 2004 to December 
      2007. Treatment outcomes were measured in terms of response rates, overall 
      survival (OS) and progression-free survival (PFS). Overall and PFS were 
      calculated with Kaplan-Meier methodology and Cox-proportional hazards model was 
      used for multivariate analysis to identify prognostic factors. RESULTS: There 
      were 125 patients (males 77%) who received minimum one cycle of chemotherapy with 
      median age of 32 years (Range 15-65 years). Stage IV disease was seen in (46 
      patients) 37%; 75% (94 patients) patients had B symptoms. International 
      prognostic score (IPS) </=4 was seen in 95/112 (85%) patients. ABVD (adriamycin, 
      bleomycin, vinblastine, dacarbazine) chemotherapy was given to 94%. Radiation to 
      residual/bulky sites was given to 36% (45 patients). Response data was available 
      for 112 patients; complete response in 76%; partial response in 10 % and 
      progressive disease in 3 patients. Nineteen deaths (progressive disease-7, 
      toxicity-8, unrelated cause-4) were observed. At median follow-up of 28 months, 
      estimated 5-year OS and PFS were 60% and 58%, respectively. On multivariate 
      analysis, IPS and response to treatment were significant factors for both OS and 
      PFS. CONCLUSIONS: The treatment outcomes in this study are comparable with the 
      published literature with limited follow-up data.
FAU - Jain, H
AU  - Jain H
AD  - Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.
FAU - Sengar, M
AU  - Sengar M
FAU - Nair, R
AU  - Nair R
FAU - Menon, H
AU  - Menon H
FAU - Laskar, S
AU  - Laskar S
FAU - Shet, T
AU  - Shet T
FAU - Gujral, S
AU  - Gujral S
FAU - Sridhar, E
AU  - Sridhar E
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Postgrad Med
JT  - Journal of postgraduate medicine
JID - 2985196R
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - ABVD protocol
SB  - IM
CIN - J Postgrad Med. 2015 Apr-Jun;61(2):75-6. PMID: 25766336
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bleomycin/therapeutic use
MH  - Combined Modality Therapy/*methods
MH  - Dacarbazine/therapeutic use
MH  - Disease-Free Survival
MH  - Doxorubicin/therapeutic use
MH  - Female
MH  - Hodgkin Disease/*drug therapy/pathology/radiotherapy
MH  - Humans
MH  - India
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Neoplasm Staging
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vinblastine/therapeutic use
PMC - PMC4943438
COIS- Conflict of Interest: None declared.
EDAT- 2015/03/15 06:00
MHDA- 2016/07/28 06:00
PMCR- 2015/04/01
CRDT- 2015/03/14 06:00
PHST- 2015/03/14 06:00 [entrez]
PHST- 2015/03/15 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - jpgm_2015_61_2_88_150446 [pii]
AID - JPGM-61-88 [pii]
AID - 10.4103/0022-3859.150446 [doi]
PST - ppublish
SO  - J Postgrad Med. 2015 Apr-Jun;61(2):88-91. doi: 10.4103/0022-3859.150446.